AstraZeneca COVID‐19 vaccine: A possible risk factor for ischemic stroke and cerebral venous sagittal sinus thrombosis: A case series

Abstract

One of the most prevalent neurological impairments is cerebrovascular accident (CVA). Ischemic stroke and CVST have been linked to the AstraZeneca COVID-19 vaccine. Three Sudanese patients developed these diseases after receiving the AstraZeneca COVID-19 vaccine, indicating a relationship between the AstraZeneca COVID-19 vaccine and these conditions.

Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1

“…Siddig A reported three instances of thrombosis with thrombocytopenia after the introduction of the adenovirus vector vaccine ChAdOx1 (Oxford-AstraZeneca), all of which manifested between 8 and 14 days after the first vaccination. Ischemic stroke, cerebral venous thrombosis, and particularly sagittal sinus thrombosis were indicated in this research as the most common kinds of stroke that are likely to emerge after immunization [ 32 ].…”

COVID-19 : Embolie Pulmonaire aigue sous le vaccin Covishield à l’Hôpital du Mali Aout 2021.

“…Les autres manifestations étaient des réactions locales ou systématiques légères à modérées . Récemment, de nombreux cas de thrombose thrombopénie induite par la vaccination (VITT) ont été signalés, avec une incidence apparemment comprise entre 1 sur 125 000 et 1 sur 1 million, la plupart d'entre eux étant attribués au vaccin ChAdOx1 nCoV-19 [7][8][9] , ce qui pourrait appuyer une hypothèse de d'imputabilité des VITT au vaccin ChAdOx1 nCoV-19 étant donné que notre cas avait reçu ce même type vaccin [10] . Le VITT se présente généralement sous la forme d'une nouvelle thrombocytopénie et d'une thrombose veineuse ou artérielle confirmée dans les 4 à 16 jours suivant la vaccination contre le COVID-19 [11] , l'analyse de notre cas corrobore l'affirmation de Greinacher et al, puisque la symptomatologie de notre cas est apparue 5 jours après la vaccination avec le vaccin ChAdOx1 nCoV-19 soit dans la fourchette de 4 à 16 jours [5] .…”

Cerebral venous sinus thrombosis following intracerebral hemorrhage after COVID‐19 AstraZeneca vaccination: A case report

“… 2 It was realized that thrombocytopenia alone or thrombosis without thrombocytopenia could be part of the thrombotic events. 3 After ruling out other causes of CVST, the vaccine could be a reason to induce CVST. 4 Till April 4, 2021, European Medicine Agency's Pharmacovigilance Risk Assessment Committee reported 169 cases of CVST from all 34 million people who received the AstraZeneca COVID‐19 vaccine.…”

“…There are few clinical reports of cerebral venous sinus thrombosis (CVST) due to this viral vector vaccine 2 . It was realized that thrombocytopenia alone or thrombosis without thrombocytopenia could be part of the thrombotic events 3 . After ruling out other causes of CVST, the vaccine could be a reason to induce CVST 4 .…”